Online citations, reference lists, and bibliographies.

Discovery Of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol As An Isozyme-selective Inhibitor Of PI3K For The Treatment Of Ischemia Reperfusion Injury Associated With Myocardial Infarction.

M. Palanki, E. Dneprovskaia, J. Doukas, Richard M. Fine, J. Hood, Xinshan Kang, Dan Lohse, M. Martin, G. Noronha, R. Soll, W. Wrasidlo, Shiyin Yee, H. Zhu
Published 2007 · Medicine, Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
In studies aimed toward identifying effective and safe inhibitors of kinase signaling cascades that underlie ischemia/reperfusion (I/R) injury, we synthesized a series of pteridines and pyridopyrazines. The design strategy was inspired by the examination of naturally occurring PI3K inhibitors such as wortmannin and quercetin, and building a pharmacophore-based model used for optimization. Structural modifications led to hybrid molecules which incorporated aminopyrimidine and aminopyridine moieties with ATP mimetic characteristics into the pharmacophore motifs to modulate kinase affinity and selectivity. Elaborations involving substitutions of the 2 and 4 positions of the pyrimidine or pyridine ring and the 6 and 7 positions of the central pyrazine ring resulted in in vivo activity profiles which identified potent inhibitors of vascular endothelial growth factor (VEGF) induced vascular leakage. Pathway analysis identified a diaminopteridine-diphenol as a potent and selective phosphatidylinositol-3-kinase (PI3K) inhibitor. The structure-activity relationship studies of various analogues of diaminopteridine-diphenol-based on biochemical assays resulted in potent inhibitors of PI3K.



This paper is referenced by
10.1515/hc-2018-0039
The regioselective catalyst-free synthesis of bis-quinoxalines and bis-pyrido[2,3-b]pyrazines by double condensation of 1,4-phenylene-bis-glyoxal with 1,2-diamines
Mehdi Ahmadi Sabegh (2018)
10.1016/j.chembiol.2010.01.010
Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs.
O. Williams (2010)
10.1021/cr300176g
Arylglyoxals in synthesis of heterocyclic compounds.
Bagher Eftekhari-Sis (2013)
10.1016/B978-0-12-396521-9.00015-2
Inhibitors of the Phosphatidylinositol 3-Kinase Pathway
William A. Denny (2014)
10.1007/s00210-018-1587-0
Anti-leukemia activity of 4-amino-2-aryl-6,9-dichlorobenzo[g]pteridines
Antonio José Ruiz-Alcaraz (2018)
10.1016/j.chembiol.2016.02.015
Epiblastin A Induces Reprogramming of Epiblast Stem Cells Into Embryonic Stem Cells by Inhibition of Casein Kinase 1.
Andrei Ursu (2016)
10.1158/2159-8290.CD-15-1346
Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.
Megan M. Kaneda (2016)
10.1016/j.bmcl.2013.09.005
Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines.
L. Kékesi (2013)
10.1016/S0959-6380(09)70042-X
Chapter 6.3 (2008): Triazines, Tetrazines and Fused Ring Polyaza Systems
Dmitry N. Kozhevnikov (2009)
10.1016/j.ejmech.2013.05.020
First synthesis and biological evaluation of 4-amino-2-aryl-6,9-dichlorobenzo[g]pteridines as inhibitors of TNF-α and IL-6.
Antonio Guirado (2013)
10.1002/JHET.3135
Synthesis, Tautomerism, and Antiradical Activity of Novel Pteridinetrione Derivatives
M. S. Kazunin (2018)
10.1007/s10593-019-02473-x
Amides of substituted 3-(pteridin-6-yl)propanoic acids: synthesis, spectral characteristics, and cytotoxic activity
M. S. Kazunin (2019)
10.4155/fmc.15.104
Pteridine-2,4-diamine derivatives as radical scavengers and inhibitors of lipoxygenase that can possess anti-inflammatory properties
E. Pontiki (2015)
10.1016/j.ccr.2011.04.016
Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.
Michael C Schmid (2011)
10.1021/jm300847w
PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases.
T. D. Cushing (2012)
10.3892/mmr.2013.1649
Phosphoinositide 3-kinase δ/γ inhibition does not prevent concanavalin A-induced hepatitis.
Y. Liu (2013)
Rational design, re-engineering and characterisation of tetrahydrofolate riboswitches in bacteria
James Leigh (2015)
10.1111/j.1755-5922.2010.00206.x
PI3K inhibitors in cardiovascular disease.
A. Eisenreich (2011)
10.1016/j.bmcl.2012.05.121
Discovery of novel PI3Kγ/δ inhibitors as potential agents for inflammation.
Katie Ellard (2012)
10.4155/fmc.09.5
Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
S. Maira (2009)
10.1021/acs.joc.7b00081
Copper-Catalyzed Regioselective C-H Sulfonyloxylation of Electron-Rich Arenes with p-Toluenesulfonic Acid and Sulfonyloxylation of Aryl(mesityl)iodonium Sulfonates.
He Yan Huang (2017)
10.1021/jm501624r
Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease.
T. D. Cushing (2015)
Discovery of Dual Inhibitors of the Immune Cell PI 3 Ks p 110 d and p 110 g : a Prototype for New Anti-inflammatory Drugs
O. Williams ()
10.1016/S0065-7743(09)04417-0
Chapter 17 Emerging Therapies Based on Inhibitors of Phosphatidyl-Inositol-3-Kinases
John M. Nuss (2009)
10.1080/10408390903584094
Effects of Flavonoids and other Polyphenols on Inflammation
R. González (2011)
10.1039/C2MD20044A
Small molecules targeting phosphoinositide 3-kinases
Peng Wu (2012)
10.1016/J.BBAPAP.2007.10.003
Targeting phosphoinositide 3-kinase: moving towards therapy.
R. Marone (2008)
10.4155/fmc.14.28
Selective and potent small-molecule inhibitors of PI3Ks.
Yujeong Jeong (2014)
10.1039/C5MD00424A
Efficient synthesis of novel disubstituted pyrido[3,4-b]pyrazines for the design of protein kinase inhibitors
Maud Antoine (2016)
10.1158/2159-8290.CD-15-0827
Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.
Andrew J. Gunderson (2016)
10.1016/J.SCP.2019.100162
Dissolution of cellulose in ionic liquids and their mixed cosolvents: A review
C. Verma (2019)
10.1002/med.21341
Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond.
Manman Wei (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar